Thymosin Alpha-1

A 28-amino-acid peptide originally isolated from the thymus gland, the organ that trains your T cells. Thymosin alpha-1 modulates the immune system rather than simply boosting it: it enhances T-cell maturation, increases CD4 counts, activates dendritic cells, and reduces markers of T-cell exhaustion. The synthetic version is manufactured and sold as an approved drug in multiple countries for hepatitis B and as an immune adjunct.

In the healing column it is an outlier. BPC-157 and TB-500 are tissue-repair peptides that happen to lack human data. Thymosin alpha-1 is the reverse: it has real human data, but for immunity, not repair. The peptide community groups them together because they are all injectable peptides in the same vendor catalogs, and because immune support during recovery is a reasonable idea. Just know that the evidence base and the marketing are telling two different stories.

The richest evidence base in this column, all of it for immune modulation:

The community runs 1.6 mg subcutaneously two to three times a week, which tracks the approved hepatitis B schedule. There is no loading phase, no titration needed. Cycles of four to twelve weeks are typical for immune support during periods of high stress, illness, or alongside other therapies, with some people running longer during chronic illness. Reconstitute with bacteriostatic water and refrigerate.

Daily-life notes: if you are starting it during an illness, earlier is better, the trial evidence is in acute settings. If you are on a steroid course, be aware that corticosteroids suppress the immune activity thymosin alpha-1 is trying to enhance, so the timing matters. Running it through a vaccination is a reasonable idea and consistent with its adjuvant use in clinical settings.

The best-characterized safety profile in this column. Across trials totaling hundreds of participants, no serious drug-related adverse events were recorded: